A Potent Neutralizing Monoclonal Antibody to Human Growth Hormone Suppresses Insulin-Like Growth Factor-1 in Female Rats
Endocrinology · 29.03.2024 · 165 (5)
DOI: 10.1210/endocr/bqae033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, online erschienen am 19.03.2024. Verfasst von Tomoyuki Hata und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama 331-9530, Japan. Hauptthemen laut MEDLINE: Human Growth Hormone, Acromegaly, Gigantism. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Taisho Pharmaceutical Co, Ltd.
Abstract (Originalsprache)
Acromegaly and gigantism are disorders caused by hypersecretion of growth hormone (GH), usually from pituitary adenomas. Although somatostatin analogues (SSA), dopamine agonists, and GH receptor antagonists are important therapeutic agents, all of these have issues with their effectiveness, safety, and/or convenience of use. To overcome these, we developed a GH-specific potent neutralizing a mouse monoclonal antibody (mAb) named 13H02. 13H02 selectively bound both to human and monkey GH with high affinity, and strongly inhibited the biological activity of GH in the Nb2 rat lymphoma cell proliferation assay. In hypophysectomized/GH-supplemented rats, a single subcutaneous administration of 13H02 significantly and dose-dependently lowered the serum insulin-like growth factor-1 levels. To pursue the therapeutic potential of this antibody for acromegaly and gigantism, we humanized 13H02 to reduce its immunogenicity and applied a single amino acid mutation in the Fc region to extend its serum half-life. The resulting antibody, Hu-13H02m, also showed GH-specific neutralizing activity, similar to the parental 13H02, and showed improved binding affinity to human FcRn.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama 331-9530, Japan.
ORCID-Profile: Tomoyuki Hata
Förderung
- Taisho Pharmaceutical Co, Ltd
Zitieren
APA
Hata, T., Uematsu, Y., Sugita, A., Adachi, H., Kato, S., Hirate, M., Ishikura, K. I., Kaku, A., Ohara, H., Kojima, N., Takahashi, T., & Kurokawa, T. (2024). A Potent Neutralizing Monoclonal Antibody to Human Growth Hormone Suppresses Insulin-Like Growth Factor-1 in Female Rats. Endocrinology, 165(5). https://doi.org/10.1210/endocr/bqae033
Vancouver
Hata T, Uematsu Y, Sugita A, Adachi H, Kato S, Hirate M, et al. A Potent Neutralizing Monoclonal Antibody to Human Growth Hormone Suppresses Insulin-Like Growth Factor-1 in Female Rats. Endocrinology. 2024;165(5). doi:10.1210/endocr/bqae033
BibTeX
@article{Hata2024,
author = {Hata, Tomoyuki and Uematsu, Yoshikatsu and Sugita, Ayumi and Adachi, Hisashi and Kato, Sayaka and Hirate, Maki and Ishikura, Kei-Ichiro and Kaku, Ayaka and Ohara, Hiroki and Kojima, Naoki and Takahashi, Teisuke and Kurokawa, Tomofumi},
title = {A Potent Neutralizing Monoclonal Antibody to Human Growth Hormone Suppresses Insulin-Like Growth Factor-1 in Female Rats},
journal = {Endocrinology},
year = {2024},
volume = {165},
number = {5},
doi = {10.1210/endocr/bqae033}
}
EUVIMED